Core Laboratories (CLB) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Core Laboratories in the last year. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" Core Laboratories stock.
View analyst ratings for Core Laboratories or view top-rated stocks.

3 brokers have issued 12-month target prices for Core Laboratories' shares. Their CLB stock forecasts range from $20.00 to $32.00. On average, they expect Core Laboratories' share price to reach $23.33 in the next year. This suggests a possible upside of 42.7% from the stock's current price.
View analysts' price targets for Core Laboratories or view top-rated stocks among Wall Street analysts.

Core Laboratories' stock was trading at $22.31 at the start of the year. Since then, CLB shares have decreased by 26.7% and is now trading at $16.35.
View the best growth stocks for 2022 here.

Core Laboratories saw a increase in short interest in July. As of July 15th, there was short interest totaling 5,170,000 shares, an increase of 25.8% from the June 30th total of 4,110,000 shares. Based on an average daily trading volume, of 457,700 shares, the days-to-cover ratio is currently 11.3 days. Approximately 11.2% of the company's stock are sold short.
View Core Laboratories' Short Interest.

Core Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our earnings forecast for Core Laboratories.

Core Laboratories (NYSE:CLB) released its earnings results on Wednesday, July, 27th. The oil and gas company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by $0.02. The oil and gas company had revenue of $120.90 million for the quarter, compared to analyst estimates of $121.35 million. Core Laboratories had a trailing twelve-month return on equity of 16.12% and a net margin of 1.82%. Core Laboratories's revenue for the quarter was up 1.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.18 EPS.

Core Laboratories announced a quarterly dividend on Friday, July 29th. Stockholders of record on Monday, August 8th will be given a dividend of $0.01 per share on Monday, August 29th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date is Friday, August 5th.
View Core Laboratories' dividend history.

Core Laboratories(NYSE:CLB) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.24%. The dividend payout ratio of Core Laboratories is 21.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Core Laboratories will have a dividend payout ratio of 3.92% next year. This indicates that Core Laboratories will be able to sustain or increase its dividend.
View Core Laboratories' dividend history.

Core Laboratories updated its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $0.13-$0.18 for the period, compared to the consensus estimate of $0.20. The company issued revenue guidance of $123.00 million-$129.00 million, compared to the consensus revenue estimate of $125.12 million.

60 employees have rated Core Laboratories CEO David M. Demshur on Glassdoor.com. David M. Demshur has an approval rating of 36% among Core Laboratories' employees. This puts David M. Demshur in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Core Laboratories investors own include CA (CA), BlackRock (BLK), Starbucks (SBUX), Micron Technology (MU), Chipotle Mexican Grill (CMG), Endologix (ELGX), Intel (INTC), Netflix (NFLX), AT&T (T) and Gilead Sciences (GILD).

Core Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLB."

Core Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Boston Trust Walden Corp (4.30%), Van ECK Associates Corp (4.14%), Douglas Lane & Associates LLC (1.19%), Congress Asset Management Co. MA (1.10%), Truist Financial Corp (0.91%) and Scout Investments Inc. (0.63%). Company insiders that own Core Laboratories stock include Gregory Barry Barnett, Jan Willem Sodderland, Lawrence Bruno and Mark F Elvig.
View institutional ownership trends for Core Laboratories.

Shares of CLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLB stock can currently be purchased for approximately $16.35.

Core Laboratories (NYSE:CLB) has a market capitalization of $757.50 million and generates $470.25 million in revenue each year. The oil and gas company earns $19.73 million in net income (profit) each year or $0.19 on an earnings per share basis.

Core Laboratories employs 3,700 workers across the globe.

Core Laboratories was founded in 1936.

Core Laboratories' mailing address is STRAWINSKYLAAN 913 TOWER A LEVEL 9, AMSTERDAM P7, 1077 XX. The official website for Core Laboratories is www.corelab.com. The oil and gas company can be reached via phone at (120) 420-3191 or via email at investor.relations@corelab.com.